Suprax is a drug owned by Lupin Ltd. It is protected by 1 US drug patent filed in 2016 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 14, 2028. Details of Suprax's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9233112 | Pharmaceutical compositions of cefixime |
Dec, 2028
(2 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Suprax's patents.
Latest Legal Activities on Suprax's Patents
Given below is the list of recent legal activities going on the following patents of Suprax.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent | 19 Feb, 2024 | US9233112 |
| Maintenance Fee Reminder Mailed | 04 Sep, 2023 | US9233112 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 10 Jul, 2019 | US9233112 |
| Patent Issue Date Used in PTA Calculation | 12 Jan, 2016 | US9233112 |
| Recordation of Patent Grant Mailed | 12 Jan, 2016 | US9233112 |
| Email Notification | 30 Dec, 2015 | US9233112 |
| Issue Notification Mailed | 22 Dec, 2015 | US9233112 |
| Email Notification | 15 Dec, 2015 | US9233112 |
| Mail Response to 312 Amendment (PTO-271) | 15 Dec, 2015 | US9233112 |
| Dispatch to FDC | 14 Dec, 2015 | US9233112 |
US patents provide insights into the exclusivity only within the United States, but
Suprax is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Suprax's family patents as well as insights into
ongoing legal events
on those patents.
Suprax's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Suprax's generic launch date based on the expiry of its last outstanding patent is estimated to be Dec 14, 2028 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Suprax Generic API suppliers:
Cefixime is the generic name for the brand Suprax. 7 different companies have already filed for the generic of Suprax, with Lupin Pharms having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Suprax's generic
How can I launch a generic of Suprax before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Suprax's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Suprax's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Suprax -
| Strength | Submission Date | Expiration Date of Last Qualifying Patent | 180-Day Status | First Applicant Approval | Generic Competition Status |
|---|---|---|---|---|---|
| 22 Jul, 2016 | 14 Dec, 2028 | Deferred | 06 Feb, 2017 | Less |
About Suprax
Suprax is a drug owned by Lupin Ltd. It is used for treating bacterial infections. Suprax uses Cefixime as an active ingredient. Suprax was launched by Lupin in 2013.
Approval Date:
Suprax was approved by FDA for market use on 20 February, 2013.
Active Ingredient:
Suprax uses Cefixime as the active ingredient. Check out other Drugs and Companies using Cefixime ingredient
Treatment:
Suprax is used for treating bacterial infections.
Dosage:
Suprax is available in for suspension form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 500MG/5ML | FOR SUSPENSION | Prescription | ORAL |